Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
AVTXthis companyAvalo Therapeutics, Inc.	$7.06	-3.11×	2.93×	4,125.96×	-2.96×	-86.6%	100.0%	-123601.7%	-132642.4%	-94.2%	-70.2%	-21.1%	0.03×	0.17×	0×	8.14×	0.0%	2	3.89	2	C+
ACRSAclaris Therapeutics, Inc.	$4.13	-5.68×	3.58×	47.18×	-5.45×	-120.4%	73.3%	-975.9%	-829.6%	-63.0%	-57.7%	-12.8%	0.02×	0.28×	0×	5.28×	0.0%	3	-0.36	1	D+
ANABAnaptysBio, Inc.	$47.43	-70.26×	24.14×	3.83×	9.73×	-640.2%	99.0%	20.4%	-5.6%	-35.6%	14.6%	2.2%	0.38×	-3.24×	0.6×	9.07×	0.0%	5	2.2	3	B
ELDNEledon Pharmaceuticals, Inc.	$2.70	-2.7×	1.52×	0×	-2.24×	-91.7%	0.0%	0.0%	0.0%	-56.3%	-55.1%	-50.4%	0.01×	0.49×	0×	7.4×	0.0%	1	-4.24	2	C
IMUXImmunic, Inc.	$7.78	-0.86×	-12.46×	0×	-0.7×	-92.5%	0.0%	0.0%	0.0%	1456.2%	1693.4%	-103.4%	-0.1×	0.15×	0×	0.75×	0.0%	2	-5.29	2	C
ODTXOdyssey Therapeutics, Inc.	$19.57	-3.05×	-0.93×	152.07×	-3.03×	-100.4%	100.0%	-5415.2%	-4994.9%	30.4%	-64.4%	-28.9%	-0.06×	0.1×	-9,479.76×	7.2×	0.0%	—	—	2	C
Peer median	—	-3.05×	1.52×	3.83×	-2.24×	-100.4%	73.3%	0.0%	-5.6%	-35.6%	-55.1%	-28.9%	0.01×	0.15×	0×	7.2×	0.0%	3	-2.3	2	—